home · filing · 0001199835-22-000082
8-K
filed February 8, 2022, 6:59 PM ET
ticker FTSP
CIK 0001319643
leadership
confidence high
sentiment neutral
materiality 0.60
Lode-Star appoints Samuel Sternheim as director, CFO, and Corporate Secretary
FinTrade Sherpa, Inc.
Samuel Sternheim appointed to the Board of Directors effective January 14, 2022.
He also becomes Corporate Secretary, Chief Financial Officer, and Treasurer.
Sternheim has been CFO of Sapir Pharmaceuticals since 2015, overseeing fundraising and acquisitions.
Appointment is in connection with the previously announced acquisition of Sapir Pharmaceuticals (Dec 30, 2021).
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2022-01-14
Filed February 8, 2022, 6:59 PM ET
it has appointed Mr. Samuel Sternheim as a member of the Board of Directors effective January 14, 2022.
Appointed
Samuel Sternheim
Chief Financial Officer
FTSP ·
FinTrade Sherpa, Inc.
Effective 2022-01-14
Filed February 8, 2022, 6:59 PM ET
Mr. Sternheim will also be assuming the roles of Corporate Secretary, Chief Financial Officer and Treasurer.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Samuel Sternheim was appointed as Member of the Board of Directors at FinTrade Sherpa, Inc..
Action appointed
Role Member of the Board of Directors
Exact text from the filing
it has appointed Mr. Samuel Sternheim as a member of the Board of Directors effective January 14, 2022.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Samuel Sternheim was appointed as Chief Financial Officer at FinTrade Sherpa, Inc..
Action appointed
Role Chief Financial Officer
Exact text from the filing
Mr. Sternheim will also be assuming the roles of Corporate Secretary, Chief Financial Officer and Treasurer.
View on SEC.gov
Source: SEC EDGAR
accession 0001199835-22-000082
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.